Amylin And Takeda Team Up In Obesity
This article was originally published in The Pink Sheet Daily
Executive Summary
Obesity research space is red hot, and now one of the key players has signed a big pharma partner; under the deal Amylin will get $75 million upfront.
You may also be interested in...
Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."
Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."
More Obesity Setbacks For Amylin And Takeda
Neither Amylin Pharmaceuticals Inc. nor its Japanese partner Takeda Pharmaceutical Company Limited has had an easy time of late with diabetes and obesity R&D, and the hold on development for their joint obesity combination therapy shows prospects aren't improving for the firms or the field